Celtrix Laboratories
Executive Summary
Completes public offering of 2.1 mil. shares at $ 8.75 per share. The managing underwriters were Robertson, Stephens & Company and Oppenheimer & Co. Palo Alto, Cal.-based Celtrix started as a division of Collagen and later became a wholly owned subsidiary before it was spun off from Collagen on Feb. 15. Celtrix said it is currently developing potential products using transforming growth factor beta for the treatment of detached retinas, dermal ulcers and osteoporosis.